An interventional study of Mobile health application and Fitbit + standard of care and Standard of care in Pancreatic Cancer, Gastric Cancer and Hepatic Cancer, sponsored by Weill Medical College of Cornell University. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Other
Study is paused for interim analysis.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University — none open to participants now, none under way, none of them phase 3. Pancreatic Neoplasms · Weill Medical College of Cornell University.
Among the 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University, this one is one of 3 that started in 2017, is one of 4 with no phase, and was the 8th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →None of the 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University is open now. The open studies under Pancreatic Neoplasms, anywhere →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 29 across the 7 interventional studies, 1,000 across the 3 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.
Patients will be randomized to 1) standard of care or 2) to use our mobile app with standard care. The mobile app will collect information on patients' daily physical activity patterns and health status data for clinicians using smartphone mobile technology applications. The investigators believe that by tracking information on patients, the investigators may be able to intervene sooner and prevent a delay in care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
Other: Mobile health application and Fitbit + standard of care
Participants will receive standard of care
Other: Standard of care
Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
Post-operative standard of care information
Readmission rate
Investigators will track readmission rates after surgery for those on the trial
Time frame: 30 days
Healthcare utilization rates
Investigators will track patients' healthcare resource utilization and the cost of this utilization by assessing how often the patients contact their providers via phone or the app, access the emergency room, and through readmission data.
Time frame: 30 days
Patient Satisfaction with Device
Investigators will assess patients' satisfaction with their care experience and device. This will be done with an internal questionnaire asking if patients were satisfied and if they found it easy to use.
Time frame: 30 days
Quality of life: Return to Baseline Function-Walking
Investigators will monitor patients' return to baseline health after surgery by tracking progress via step counts, as monitored by a FitBit tracker.
Time frame: 30 days
Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs)
Investigators will monitor patients' return to baseline health after surgery by tracking progress using a questionnaire, modified from the Katz Activities of Daily Living scale. For this scale, a score of 6 is high, indicating that the patient is independent and a score of 0 is low, indicating that the patient very dependent in performing their ADLs.
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started May 2017 (actual). Primary completion is estimated for Mar 2027, 118 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jun 2026 → Mar 2027 and completion Jun 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Study is paused for interim analysis.
Study is paused for interim analysis.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →